Roivant Sciences (NASDAQ:ROIV) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Roivant Sciences (NASDAQ:ROIV) released its quarterly earnings data on Monday. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.04, Zacks reports. Roivant Sciences had a net margin of 3,827.42% and a negative return on equity of 14.65%.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV opened at $10.89 on Monday. The firm has a market cap of $7.93 billion, a P/E ratio of 1.93 and a beta of 1.25. Roivant Sciences has a 1 year low of $9.76 and a 1 year high of $13.06. The firm’s 50 day moving average price is $11.51 and its 200 day moving average price is $11.60.

Insider Buying and Selling at Roivant Sciences

In related news, CIO Mayukh Sukhatme sold 185,946 shares of the firm’s stock in a transaction that occurred on Tuesday, December 24th. The shares were sold at an average price of $12.00, for a total value of $2,231,352.00. Following the sale, the executive now directly owns 18,836,547 shares of the company’s stock, valued at approximately $226,038,564. This trade represents a 0.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Eric Venker sold 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $11.32, for a total transaction of $1,132,000.00. Following the transaction, the chief operating officer now directly owns 606,525 shares of the company’s stock, valued at $6,865,863. This trade represents a 14.15 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 1,942,629 shares of company stock worth $23,034,486. Insiders own 7.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ROIV. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a research report on Thursday, January 30th. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research report on Wednesday, November 13th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $17.93.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.